Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Aug 27;7(11):e1507668. doi: 10.1080/2162402X.2018.1507668

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

PMC Copyright notice

Figure 4. — Chemokine levels are influenced by Dex-treatment. (A) Serum samples from healthy donors (HD) or Dex-treated and naïve GBM patients were analysed using the Biorad Human Chemokine Panel 40-plex. Dex-dependent differences were found in 6Ckine (CCL21), CTACK (CCL27), IP-10 (CXCL10), MCP-1 (CCL2), MDC (CCL22), MPIF-1 (CCL23), and SDF-1 (CXCL12). P-values calculated using one-way ANOVA followed by Tukey’s multiple comparisons test. Line indicates mean. (B) Representative cores from gliosis, grade I, III and GBM TMAs stained for MCP-1. (C-D) Quantitative analysis of TMAs represented as (C) % of total cells that are MCP-1+, or (D) number of MCP-1+ cells per square millimeter. P-values calculated with the Kruskal–Wallis one-way ANOVA followed by Dunn’s multiple comparisons test. Line indicates median. Linear regression analysis of MCP-1 versus CD163 positivity in (E) grade I pilocytic astroctyoma and (F) GBM. P-values indicate the slope does not significantly deviate from zero. Comparison of MCP-1 positivity in Dex treated and Dex naïve samples from (G) gliosis (H) grade I, and (I) grade II-III TMAs.